definiens: defined for p urposes of this Agreement as a party controlling, c ontrolled by or under common control with [COMPANY] ), distributo r, licensee or sublicensee ( [COMPANY] and each such other entity referred to as a ) of a drug product which contains bryostatin-1, for the treat ment of B - cell Acute Lymphoblastic Leukemia, CD22 directed CAR - T m ono - therapies ( a ), [COMPANY] will pay Neurotrope two percent ( 2 % ) of the gross r evenues received by each Selling Entity from the sa le by such Selling Entity of such Bryostatin Product ( the ), provided that when a Bryostatin Prod uct is sold by a Selling Entity as a combination therapy with a t least one additional active pharmaceutical ingred ient, the Revenue Share as to such sale will be calculated an d will be payable only upon gross revenues of the b ryostatin-1 drug product component of such combination therapy Bryostatin Product ; provided, however, that if the gross revenues of the bryostatin-1 drug product component of such combination therapy Bryostatin Product can not reasonably be determined, then the Revenue Share wi ll be calculated and will be payable upon the comme rcial value of such bryostatin-1 drug product portion of such combination therapy Bryostatin Product as Bryo Logyx and Neurotrope will in good faith agree in writing, based upon commercial precepts applicable to the p ricing of similar combination therapy products . Such Revenue Share will be payable by [COMPANY] to Neurotrope un til such date as the aggregate cumulative amount of Rev enue Share paid by [COMPANY] to Neurotrope reaches One Million Dollars ( $ 1,000,000.00 ) ( the ) . P ayments based on sales of Bryostatin Products or an y other payments will not be required to be made by BryoLog yx to Neurotrope after the End Date